Electra Therapeutics Inc ETRA

$8.98 +0.46 (5.40%)

Valuation

Market cap
525,360,000
Revenue TTM
$0
Net income TTM
$-61,975,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
177,300
Avg volume
—
Day's range
$8.36 – $9.21
Shares out
62,767,000
Stochastic %K
59%
Beta
—
Analysts
Strong Buy
Price target
$33.50

Price

Company profile

Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an appro...

Show more

Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(888) 743-2290
Website
https://electra-therapeutics.com
Address
230 E Grand Avenue, Suite S-100, South San Francisco, United States

Latest news

Stocktwits

openmarketalerts Nov 6, 2:07 PM
Insider cluster buys filed Thu, Nov 5 $UPBD Upbound Group — 7 insiders bought $1.4M (Oct 27 – Nov 3) $LBTYA Liberty Global — 2 insiders bought $3.0M (Nov 4) $BXMT Blackstone Mortgage Trust — 2 insiders bought $1.1M (Nov 4) $FBRT Franklin Bsp Realty Trust — 2 insiders bought $1.0M (Nov 2–3) $ETRA Electra Therapeutics — 2 insiders bought $7.2M (Nov 3–5) Open-market purchases from SEC filings. No stock grants, no option exercises, no pre-scheduled 10b5-1 plan trades.
0 replies
openmarketalerts Nov 5, 10:54 PM
$ETRA: $3.6M of stock bought by Director Orbimed Advisors LLC from Nov 3 to Nov 5. 472,571 shares.
0 replies
FilingTracker Nov 5, 10:41 PM
$ETRA $3.61 million insider purchase: https://filingtracker.ai/filing/1055951/0000947871-26-000985?doc=ownership.xml
0 replies
SemperFidelity Nov 4, 7:15 PM
$ETRA 👍 https://stocks.apple.com/Ad8wpCzcgSnS-fZkdWc0dhQ
1 replies
StockScanners Nov 4, 1:02 AM
$ETRA keep watch if this holds above 7.54
0 replies
SemperFidelity Oct 14, 6:21 PM
$ETRA see how this ages …🍷
0 replies
justiceforb_85 Sep 23, 1:00 AM
$ETRA significantly undervalued based on current MC based on the data presented for ipsoprubart in sHLH and the potential for treatment of T/NK cell lymphomas.
1 replies
theflynews Sep 21, 8:03 PM
Opening Day: Electra Therapeutics, Orion180 make market debuts - $ETRA - https://thefly.com/ETRA
0 replies